摘要
Objective: To study the influence of helicobacter pylori (HP) infection on plaque property of patients with coronary heart disease and its correlation with inflammatory response and oxidative stress response. Methods: Patients who underwent coronary CTA examination and were diagnosed with coronary heart disease in Central Hospital of China National Petroleum Corporation between March 2015 and August 2017 were selected as the research subjects, 14C urea breath test was used to judge the HP infection, coronary CTA examination was used to judge coronary atheromatous plaque properties, and serum specimens were collected to determine inflammatory response indexes and oxidative stress response indexes. Results:The proportion of soft plaques in HP positive patients was significantly higher than that in HP negative patients whereas the proportion of fibrous plaques and calcified plaques were significantly lower than those in HP negative patients;serum SIRT1 and SOD contents of coronary heart disease patients with soft plaques were significantly lower than those of patients with fibrous plaques and calcified plaques whereas MPO, MDA and ET-1, Gal-3, MIP-1α, IL-17 and sICAM1 contents were significantly higher than those of patients with fibrous plaques and calcified plaques;serum SIRT1 and SOD contents of coronary heart disease patients with fibrous plaques were significantly lower than those of patients with calcified plaques whereas MPO, MDA, ET-1, Gal-3, MIP-1α, IL-17 and sICAM1 contents were significantly higher than those of patients with calcified plaques. Serum SIRT1 and SOD contents of patients with HP positive coronary heart disease were significantly lower than those of patients with HP negative coronary heart disease whereas MPO, MDA, ET-1, Gal-3, MIP-1 , IL-17 and sICAM1 contents were significantly higher than those of patients with HP negative coronary heart disease. Conclusion: Helicobacter pylori infection can reduce the plaque stability and activate the inflammatory response and oxidative stress response in patients with coronary heart disease.
